Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

SLDB earnings analysis

Filed May 12, 2026 · Our reading of the company's report

The latest report

Solid Biosciences reported a net loss of $56.7 million for Q1 2026, up from a $39.3 million loss in Q1 2025, reflecting increased operational expenses in R&D and G&A. The company continues to advance its gene therapy…

Read full summary

Solid Biosciences reported a net loss of $56.7 million for Q1 2026, up from a $39.3 million loss in Q1 2025, reflecting increased operational expenses in R&D and G&A. The company continues to advance its gene therapy pipeline for Duchenne muscular dystrophy, Friedreich's ataxia, and catecholaminergic polymorphic ventricular tachycardia, with feasibility and clinical trials ongoing. Cash resources were reported at $380.7 million, which the company believes will sustain operations through 2028.

Read the original on SEC.gov

Reported figures

Earnings per share
$-0.43

What stood out

  • Q1 Revenue and Loss Numbers

    Reported a net loss of $56.7 million for Q1 2026, compared to a loss of $39.3 million in Q1 2025.

  • Increased R&D Spending

    R&D expenses increased to $46.1 million in Q1 2026 from $30.9 million in Q1 2025, mainly due to increased costs for SGT-003.

  • Strong Cash Position

    Solid has $380.7 million in cash and cash equivalents, expected to fund operations through the first half of 2028.

  • Clinical Trial Progress

    Phase 1/2 trial for SGT-003 shows promising interim results; the trial has dosed 47 participants so far.

  • Milestone Payments Fulfilled

    Payments made in stock to FA212 LLC upon reaching development milestones for SGT-212.

  • No Debt Reported

    As of March 31, 2026, the company had no outstanding debt.

What to watch

  • Patient Enrollment Challenges

    Recruitment for clinical trials may face delays, negatively impacting drug development timelines.

  • Regulatory Scrutiny Risks

    Increased scrutiny and potential litigation regarding gene therapy development may impact operational risks.

  • Cost Containment and Pricing Pressure

    Legislative measures could impose significant price reductions, affecting revenue generation potential.

Management's outlook

Outlook indicates future operational capacity but no specific guidance on revenue or earnings.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.